Ligand Pharmaceuticals (LGND) Acquisitions (2011 - 2024)

Ligand Pharmaceuticals (LGND) reported Acquisitions of -$92.0 million for Q4 2024, down 124.34% sequentially from $378.0 million in Q4 2020.

Ligand Pharmaceuticals (LGND) Acquisitions (2011 - 2024) Analysis & Trends

Ligand Pharmaceuticals (LGND) has 7 years of Acquisitions data on file, last reported at -$92.0 million in Q4 2024.

For the quarter ending Q4 2024, Acquisitions changed N/A year-over-year to -$92.0 million; the trailing twelve-month figure through Dec 2024 stood at -$92.0 million (changed N/A YoY), and the FY2023 full-year result was $10.4 million, changed N/A from the prior year.
Acquisitions slipped to -$92.0 million in Q4 2024, from $378.0 million in the prior quarter.
In the past five years, Acquisitions ranged from a high of $378.0 million in Q4 2020 to a low of -$92.0 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Acquisitions (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Ligand Pharmaceuticals	6.05 Bn	5.27 Bn	48.45 Mn	-

Download Data